Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report
Vectus's quarterly report, dated 29 October 2026, said the US Food and Drug Administration had granted its request for a pre-IND Type B meeting on VB0004 in idiopathic pulmonary fibrosis. Written FDA responses are expected by mid-November 2026. The company has appointed Cardinal Health …
Vectus said the US Food and Drug Administration had granted its request for a pre-IND Type B meeting covering the proposed development programme for VB0004 in idiopathic pulmonary fibrosis. The interaction will take the form of written responses from the FDA, which are expected …
The company said its US Phase III chronic wound trial had approximately 112 patients randomised, with recruitment continuing. It is pursuing a medical device pathway as an alternative route to approval, with a US FDA 510(k) submission targeted for April 2027 and a European …
On 3 November 2026 Clever Culture said it had secured commitments for a $2.6 million funding package before costs to accelerate development of APAS Revolution. The package combines a targeted $1.0 million capital raise with a $1.6 million unsecured loan repayable on 30 November …
The company had submitted its EchoSolv HF application to the FDA in December 2025 and issued follow-up application updates in September and October 2026. The detail helps establish the scale and scope of the activity rather than reducing the update to a single headline …
Medibank operates private health insurance products under the Medibank and ahm brands. Its broader healthBusinessincludes services and partnerships intended to improve access to care beyond traditional hospital settings. The company describes its current reach as around six million people receiving support with health and …
The FDA completed its review of Imricor's third Premarket Approval module, which covers the design, execution and results of non-clinical bench testing for the Vision-MR Ablation Catheter 2.0, the RF-5000 System and the RF-5000 Irrigation Tubing Set. Imricor submitted the module on 11 June …
The company said the United States Food and Drug Administration granted Breakthrough Therapy designation to 64Cu-SAR-bisPSMA for positron emission tomography of PSMA-positive lesions in men with prostate cancer and suspected recurrence based on elevated PSA. Clarity described it as the first Breakthrough Therapy designation …
The refund, described by the company as non-dilutive funding, adds meaningfully to the proceeds from the company's recentCapitalraise, which was completed in September and October 2026. Together, these funding sources are intended to underpin the continued development of PTX-100 as it progresses through its …
The TGA performs audit inspections of manufacturing procedures and facilities to ensure compliance with regulatory standards applicable to the clinical trial supply of therapeutic goods for Australian patients. The completion of this audit at Q-Gen represents one of the critical steps in the technology …
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!
Hi! How can we help you today?
Loading…